Collaboration Funding. GSK shall be responsible for paying ARIDIS’ Development Costs specified in the budget incurred solely in connection with the conduct of the Collaboration Program (and not for activities outside of the conduct of the Collaboration Program or in furtherance of ARIDIS’ existing collaborations with Third Parties) in accordance with the applicable budget agreed upon by the Parties as specified in Exhibit B (the “Collaboration Funding”). GSK shall pay ARIDIS for the Collaboration Funding as set forth in Section 6.2. For the avoidance of doubt, GSK shall be responsible for all costs and expenses incurred by GSK to conduct the Collaboration Program.
Collaboration Funding. As consideration for the performance by Tekmira of its obligations under the Collaboration, Alnylam agrees to fund the FTEs provided by Tekmira as follows:
(a) During the Collaboration Term, the compensation to Tekmira for up to [**] FTEs in each Contract Year of the Collaboration Term to perform its obligations under the Collaboration as provided in the Research Plan shall not be less than an aggregate of [**] in each such Contract Year; and
(b) the use of any additional FTEs in each Contract Year of the Collaboration Term as approved by the JRC shall be funded at the FTE Rate pro-rated to the duration that such FTEs actually perform such activities under the Collaboration in accordance with the Research Plan, and as documented by Tekmira pursuant to Section 7.5.3 below. Tekmira acknowledges and agrees that the FTE Rate reflects Tekmira’s fully-loaded costs and expenses in performing its obligations under the Collaboration and that Tekmira is solely responsible for its costs and expenses in performing its obligations under the Collaboration. However, Alnylam agrees to reimburse Tekmira for any extraordinary out-of pocket costs and expenses incurred by Tekmira in performing its obligations under the Collaboration in accordance with the Research Plan to the extent that such costs and expenses are approved by the JRC in advance in writing and are reasonable, documented costs and expenses actually and directly incurred by Tekmira. After the Collaboration Term, Alnylam’s funding obligation shall cease and (to the extent mutually agreed by the Parties) each Party shall be responsible for funding its own participation in the Collaboration and all expenses incurred by such Party in connection therewith.
Collaboration Funding. The Collaboration Funds shall be applied by Isis solely towards the Collaboration and in accordance with the Collaborative Research Plan.
Collaboration Funding. Monsanto shall pay, or cause to be paid, to Alnylam a one-time, non-refundable payment of [**] Dollars ($[**]). Such payment shall be made in accordance with the payment schedule for deliverables set forth in the Discovery Collaboration agreement, but in no event later than [**] months after the Effective Date.
Collaboration Funding. In consideration of the performance by Translate Bio of the Translate Bio Collaboration Activities in the Collaboration, Sanofi shall pay Translate Bio the agreed sum set out in the Collaboration Budget for each of (a) FTE Costs, (b) Out-Of-Pocket Costs, and (c) Manufacturing Costs. Each of FTE Costs, Out-Of-Pocket Costs or Manufacturing Costs is a “Cost Category”, which shall be accounted for separately by Translate Bio and in no event shall Translate Bio include costs or expenses from one such Cost Category in another such Cost Category. In the event that the Collaboration Budget or Supply Agreement includes certain Out-of-Pocket Costs or Manufacturing Costs which Translate Bio is [**], Sanofi shall [**] the full amount of those Out-of-Pocket Costs and Manufacturing Costs to Translate Bio.
Collaboration Funding. OMI will provide Collaboration funding to Isis as set forth in Section 3.5.2.
Collaboration Funding. Invitrogen shall pay to Illumina a non-refundable, non-creditable, collaboration payment of $2,300,000 (the "Collaboration Funding") in accordance with the following schedule:
(a) $1,200,000 million within fifteen (15) days of the Effective Date; and
(b) $1,100,000 within three (3) months following the Effective Date.
Collaboration Funding. 5.2.1 MERCK shall pay for all costs and expenses incurred in performance of the Drug Development Plan, including manufacture and formulation of Compound and Product, costs incurred in all research and development, preclinical and clinical trials, pre-marketing and post-marketing studies and surveillance and manufacture of clinical supplies. None of these costs and expenses shall offset or be credited against any fees, royalties or other payments required to be made by MERCK to DOV under this Agreement.
5.2.2 To the extent that MERCK determines to use DOV as a CRO, DOV and MERCK shall negotiate competitive rates for the performance of such functions in connection with the negotiation of a definitive agreement pursuant to Section 2.2.
Collaboration Funding. In consideration for Genetronics’ performance of its obligations under the Collaboration, upon the terms and conditions contained herein, Merck shall reimburse Genetronics as approved by the Committee. For any work that the Parties agree shall be performed by Genetronics or a Third Party contractor under the direction of Genetronics and paid for by Merck, the rate per FTE shall be $[*].
Collaboration Funding. BMX shall fund the research work at AFFX pursuant to the Agreed Budget and Agreed Workplan on an annual basis at a level of not less than [ * ] FTEs at AFFX's facility for a period of not less that [ * ] years. BMX may request that AFFX assign additional qualified staff to the Collaboration, and AFFX shall endeavor to meet such requests, subject to reasonable notice and increased funding to cover added FTEs. BMX shall fund the technical support development efforts at AFFX at an initial rate equal to [ * ] per budgeted FTE per Contract Year in accordance with the Agreed Budget and Agreed Workplan. BMX may request that such [ * ] Confidential Treatment Requested by Affymetrix, Inc.
